Krystal Biotech Inc. Common Stock (KRYS)
Stock · NASDAQ · Health Care
$316.6as of 10/16/2026
Price chart
Active signals
KRYS Signal Track Record
How signals performed across all stocks →What KRYS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +5.2% | 69% | September 18, 2026 |
| Bollinger Band Breakout | 22 | +4.5% | 64% | June 26, 2026 |
| Bollinger Band BreakdownActive now | 19 | +6.1% | 63% | October 2, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +8.2% | 71% | September 15, 2025 |
| Any 20-session window (baseline) | +2.6% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bu…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 295
- Website
- www.krystalbio.com/
Fundamentals
- 1-day range
- $328.51$338.91
- Market cap
- $9.55B
- P/E (trailing)
- 40.85
- P/E (forward)
- 36.65
- EPS (trailing)
- $7.98
- Dividend yield
- —
- Beta
- 0.65
- Avg. volume
- 371.8K
How Krystal Biotech Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Krystal Biotech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Targetbenzinga · 10/15/2026
- Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)SeekingAlpha · 10/10/2026
- Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak ValueSeekingAlpha · 10/10/2026
- What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For ShareholdersYahoo · 10/8/2026
- Why Krystal Biotech (KRYS) Is Drawing Fresh AttentionYahoo · 10/8/2026
- Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x RunYahoo · 10/8/2026
- $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much TodayBenzinga · 10/6/2026
- Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?Yahoo · 10/6/2026
- Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth TodayBenzinga · 9/25/2026
Insider Activity
Insider Actions →- Catherine Mazzacco · September 14, 2026 · Grant471
- Catherine Mazzacco · September 14, 2026 · Grant1.2K
- Sutherland Everett Rand · September 14, 2026 · Grant471
- Sutherland Everett Rand · September 14, 2026 · Grant1.2K
- Mason Christopher · September 14, 2026 · Grant471
- Mason Christopher · September 14, 2026 · Grant1.2K
- Gangolli Julian S · September 14, 2026 · Grant471
- Gangolli Julian S · September 14, 2026 · Grant1.2K
- ROSSI DINO A · September 14, 2026 · Grant471
- ROSSI DINO A · September 14, 2026 · Grant1.2K
- JANNEY DANIEL · September 14, 2026 · Grant471
- JANNEY DANIEL · September 14, 2026 · Grant1.2K
- Krishnan Suma · September 4, 2026 · Sale399 @ $366.56
- Krishnan Suma · September 4, 2026 · Sale826 @ $365.41
- Krishnan Suma · September 4, 2026 · Sale1.3K @ $364.48
Institutional Ownership
March 31, 2026
- Total shares held
- 27.02M
- Total value held
- $6.77B
- Institutional holders
- 362
- Unknown4.37M
- Unknown3.94M
- Unknown2.89M
- Unknown1.31M
- Unknown1.17M
- Unknown1.15M
- Unknown824.7K
- Unknown673.5K
- Unknown644.0K
- Unknown619.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat
Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.
Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat. Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.